"While the FDA’s recent formalization of regulatory categories for a kidney disease progression test, a diabetes management app, and at-home COVID-19 tests might seem like new product approvals, the true significance lies in the detailed limitations and specific use cases established for these technologies, ensuring appropriate patient expectations and clinical application."
On July 24th, the U.S. Food and Drug Administration (FDA) published three final orders that formally established permanent regulatory categories within the Code of Federal Regulations for distinct medical technologies. These orders, while announced recently, do not represent the introduction of entirely new products or services. Instead, they codify classifications that the agency initially granted in mid-2023 for a test designed to predict the rate of chronic kidney disease (CKD) progression, a prescription-based mobile application delivering behavioral therapy for diabetes management, and at-home COVID-19 testing devices. The regulatory classifications for these technologies are now officially recorded under specific sections: 862.1223 for the kidney test, 880.5735 for the diabetes app, and 866.3984 for at-home COVID-19 tests. The primary value of these finalized orders lies not in market entry, but in the precise boundaries and limitations the FDA has delineated for each category. These restrictions are often more narrowly defined than the product names might initially suggest, providing crucial context for healthcare providers and patients alike.
The establishment of these regulatory categories is a significant, albeit nuanced, development in the landscape of medical innovation. It signifies the FDA’s commitment to providing clear frameworks for novel diagnostic and therapeutic tools, while simultaneously emphasizing the critical importance of understanding their intended use and limitations. The timing of these formalizations, occurring well after the initial classifications were granted, underscores a deliberate and thorough regulatory process. The inclusion of these classifications in the Code of Federal Regulations provides a permanent and accessible reference point, offering greater predictability for manufacturers seeking to develop similar devices and clearer guidance for clinicians and patients utilizing these technologies.
The Kidney Disease Progression Test: Prognosis Over Monitoring
The regulatory category for the kidney disease progression test originated from the submission of Renalytix AI’s KidneyIntelX.dkd in August 2020. The FDA defines this in vitro diagnostic device generically as one that measures specific analytes from human samples to assist in assessing the risk of chronic kidney disease progression. However, the agency has drawn clear and stringent boundaries around its application. The regulation explicitly states that the device is "not intended for diagnosis of any disease" and, critically, is not designed for serial monitoring of kidney disease progression or for assessing the impact of therapeutic interventions. This distinction is paramount.
Standard kidney function markers, such as estimated glomerular filtration rate (eGFR) and urine albumin levels, serve dual purposes in clinical practice: they are used to stage the severity of kidney disease and to track its trajectory over time, allowing clinicians to monitor patient response to treatment. In contrast, a prognostic test falling under this new category answers a more specific, singular question: what is the likelihood of this patient’s kidney disease worsening? It is not equipped to inform a patient about their current state of improvement or the efficacy of a prescribed medication. The FDA’s explicit prohibition against marketing this test for such purposes underscores its role as a risk-assessment tool rather than a therapeutic monitoring instrument. This ensures that patients and their physicians understand that the test provides a snapshot of future risk, not a real-time assessment of disease management or treatment effectiveness.
The Diabetes Management App: A Supportive Role, Not a Replacement
The regulatory classification for the prescription diabetes app stems from Better Therapeutics’ BT-001, which was submitted in September 2022. The FDA defines this as a prescription software device that delivers digital behavioral therapy to aid in diabetes management. The agency’s description of its intended use is notably modest, characterizing the device as "intended to provide limited secondary benefit" to patients and explicitly stating that it is "not intended to replace any primary treatment, such as diet/lifestyle changes or medication."
Further reinforcing these limitations, the required labeling for such devices mandates that they are not for standalone therapy, nor are they a substitute for prescribed treatment or medication. The labeling also specifies that individuals with unstable psychiatric disorders should not use the device, and it is not intended to treat any psychiatric disorder or symptoms. The FDA identified a particularly unusual risk associated with this category: that treatment could potentially result in anxiety, depressed mood, depression, stress, or suicidal ideation. This specific hazard list highlights the sensitive nature of behavioral therapy and explains the rationale behind the psychiatric exclusions. This underscores that while digital therapeutics can be valuable adjuncts, their role in managing complex chronic conditions like diabetes is carefully defined to complement, rather than supplant, established medical interventions.
At-Home COVID-19 Tests: Enhanced Consumer Guidance and Variant Awareness
The regulatory framework for at-home COVID-19 tests, influenced by submissions like Cue Health’s Cue COVID-19 Molecular Test (May 2022), addresses tests intended for use by lay individuals without direct healthcare provider supervision. The regulation for these tests reads as a comprehensive guide to potential pitfalls and best practices, translated into mandatory labeling requirements.
Manufacturers are now obligated to clearly state that positive results do not rule out co-infections with other respiratory pathogens, and conversely, that negative results do not exclude infection with other agents. A crucial warning emphasizes that the test is not a substitute for professional medical consultation and should not be used to determine treatment decisions without clinician oversight.
Of particular importance to consumers who store these tests at home are two key requirements. First, labels must inform users that expired tests can yield inaccurate results. Second, the accuracy of the test is contingent upon proper storage conditions, a significant consideration for kits kept in environments subject to extreme temperatures, such as hot cars or unheated garages. Manufacturers must also disclose that the likelihood of false positive results increases when community prevalence of the virus is low.
A particularly noteworthy requirement pertains to viral variants. Labeling must identify the dominant strain or variant present during the test’s performance validation. Manufacturers must warn that test accuracy may change as new viral strains emerge and advise users to consider laboratory-based PCR testing when a new variant is suspected. This necessitates continuous monitoring by manufacturers for genetic mutations and the submission of evaluations to the FDA within 48 hours upon request. The rule also incorporates emergency preparedness measures. In the event of a declared public health emergency involving SARS-CoV-2, manufacturers will have a defined timeframe to test their devices against characterized samples and publish the results, a process that will continue for three years.
The accuracy standard for these tests also has a defined floor: clinical studies must demonstrate that the lower bound of the two-sided 95% confidence interval for positive percent agreement exceeds 70%. This is a critical metric for consumers, as it implies that tests within this category can, by design, miss a substantial proportion of infections.
Implications for Patients and the Regulatory Landscape
For patients, the immediate impact of these finalized orders is minimal, as the underlying classifications and market access for the originating devices were established in 2023. The practical implications primarily affect manufacturers. By creating Class II regulatory pathways with special controls, these device types avoid the more rigorous Class III designation, which would typically require premarket approval. This classification facilitates the use of the less burdensome 510(k) premarket notification process for subsequent manufacturers seeking to market similar devices. The FDA has stated that these actions are intended to "enhance patients’ access to beneficial innovation, in part by reducing regulatory burdens."
Over time, this regulatory streamlining can foster increased competition within these categories, potentially leading to lower prices and broader availability. However, it is important to note that this does not equate to an exemption from the 510(k) review process for individual products; each new device will still require its own authorization.
The most valuable takeaways for patients lie in managing expectations. For individuals offered a kidney progression test, it is crucial to understand that it serves as a single-point risk assessment and not a tool for ongoing monitoring or treatment evaluation. They should inquire about how the test results will influence their care plan. Similarly, patients prescribed a diabetes therapy app should recognize that the FDA has categorized it as providing limited secondary benefits, intended to augment, not replace, prescribed medication and lifestyle modifications. When using at-home COVID-19 tests, consumers should diligently check expiration dates, consider the storage conditions of the kit, and be aware that a negative result during a period of significant variant circulation may be less reliable than a PCR test.
It is imperative that patients do not initiate, discontinue, or alter any medication regimens, or forgo necessary monitoring tests, based solely on the information derived from these types of devices without consulting a healthcare professional.
It is also worth noting that two of the companies whose initial submissions led to these regulatory categories have experienced well-publicized business challenges since their products were first cleared. This highlights a critical aspect of regulatory frameworks: a classification can endure and provide a pathway for future innovations even if the pioneering product faces commercial difficulties.
The Path Forward: Predicates and Competition
With comments now closed on all three final orders, the categories are officially in effect. They now serve as "predicates," meaning that future devices seeking similar clearance can reference these established classifications. The next observable developments will likely be the FDA’s 510(k) clearances for comparable devices entering the market, and potentially, any future decisions by the FDA to exempt these types of devices from premarket notification requirements.
In summary, the FDA’s recent codification of regulatory categories for a kidney progression test, a prescription diabetes app, and at-home COVID-19 tests, while finalized on July 24th, reflects classifications initially granted in 2023. The true value of these formal orders lies in the explicit limitations and specific use cases defined by the FDA, which are critical for patients to understand. The most prudent approach for individuals considering these technologies is to engage with their healthcare providers to determine how the results or the application would meaningfully impact their care. The central question that remains is the extent to which these established categories will stimulate the development and market entry of competing products.
